Forskolin decreases sensitivity of brain adenylate cyclase to inhibition by 2′,5′-dideoxyadenosine  by Stübner, Dorothee & Johnson, Roger A.
Volume 248, number 1,2, 155-161 FEB 07124 May 1989 
Forskolin decreases ensitivity of brain adenylate cyclase to 
inhibition by 2’,5’-dideoxyadenosine 
Dorothee Sti.ibner+ and Roger A. Johnson 
Department of PhysioIogy and Biophysics, State University of New York, Health Sciences Center, Stony Brook, 
NY 11794-8661, USA 
Received 17 February 1989; revised version received 25 March 1989 
The effects of forskolin on the sensitivity of adenylate cyclase to ‘P-site-mediated inhibition were studied. Stimulation 
of crude and purified preparations of adenylate cyclase by forskolin led to decreased sensitivity to inhibition by 2’,5’dide- 
oxyadenosine with enzyme from rat and bovine brain. This is in contrast with the enhancement of P-site sensitivity in- 
duced by calmodulin, divalent cations, and stable GTP analogs and is in contrast with behavior seen with enzyme from 
liver and S49 cyc- membranes. The effect of forskolin on P-site sensitivity of the brain adenylate cyclase was not depen- 
dent on the presence of G-proteins or calmodulin. It was not the consequence of proteolysis nor was it due to an obvious 
artifact in the assay procedures. This distinct behavior of the brain enzyme is most likely due to a structural difference 
in the catalytic subunit. 
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1. INTRODUCTION 
Adenosine is known to modulate adenylate 
cyclase activity through three distinct sites. Two 
cell-surface receptors, the stimulatory R, or AZ and 
the inhibitory Ri and Ai receptors, alter the activity 
of adenylate cyclase via the respective guanine 
nucleotide regulatory (CL) proteins, and a site on 
the intracellular surface of the membrane mediates 
inhibition of the catalytic subunit [l-6]. The latter 
adenosine site has been referred to as the ‘P’-site 
[l] from its evident requirement for an intact 
purine moiety. Inhibition of adenylate cyclase via 
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the P-site is independent of guanine nucleotides, is 
non-competitive with respect to metal-ATP, is 
metal dependent, and is accompanied by a 20-fold 
increase in the enzyme’s apparent affinity for free 
metal [5-81. In general, an important characteristic 
of P-site-mediated inhibition is that stimulated 
forms of adenylate cyclase are substantially more 
sensitive to inhibition than are unstimulated forms 
[6-91. This sensitization of adenylate cyclase has 
been observed by reversibly stimulatory agents, 
e.g. forskolin, Mr?, or hormones and GTP, as 
well as by agents that lead to irreversible activation, 
e.g. fluoride, stable GTP analogs, or proteolysis in 
the presence of GTPyS [6-111. A possible excep- 
tion to this may be the sperm adenylate cyclase, 
which exhibits a P-site characterized by 
non-competitive, metal-dependent inhibition, but 
which exhibits substantially reduced sensitivity to 
established P-site agonists that is not enhanced by 
stimulatory agents [5,6,12]. The sensitization that 
occurs in most tissues is likely due to conforma- 
tional changes in the enzyme’s catalytic subunit 
since forskolin, known to act at the catalytic unit, 
has been reported to potentiate inhibition by the P- 
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site agonist 2’ 5 ’ ddAdo in rabbit liver and in wild- 
type and cyc- S49 lymphoma cells by Florio and 
Ross [ 1 I], and in pigeon breast muscle by Drum- 
mond [lo]. We report here a contrasting decrease 
in the degree of inhibition by 2’5’ddAdo upon 
stimulation with forskolin in various adenylate 
cyclase preparations from brain. Possible causes 
for this counteractive action of forskolin and P-site 
agonists are discussed. 
2. MATERIALS AND METHODS 
2. I. Enzyme preparations 
Particulate adenylate cyclase from rat brain was prepared as 
described [ 131. Particulate and detergent-dispersed a enylate 
cyclases from rat brain and from bovine brain cortex were 
prepared similarly, except that for the bovine enzyme the 
homogenizing medium was changed to 20 mM TEA-HCl (pH 
7.2), 250 mM sucrose, 1 mM EDTA, 3 mM DTT and 2.5 mM 
benzamidine during the first two homogenizing steps, then to 50 
mM TEA-HCI (pH 7.4) in the third rehomogenizing step (wash- 
ed particles), and to 50 mM TEA-HCI (pH 7.4) and 1% Lubrol- 
PX, without sucrose, in the detergent extraction step. Cen- 
trifugation in the first three steps was at 17 700 x g (r,,,,,) for 30 
min and in the detergent extraction step at 30 000 x g (r,,& for 
60 min. 
The catalytic subunit of adenylate cyclase was purified from 
bovine brain cortex to near homogeneity by forskolin affinity 
chromatography followed by chromatography on wheat-germ 
lectin Sepharose, essentially as described [14]. Commercially 
available 7-0-hemisuccinyl-7-deacetylforskolin was coupled to 
Affigel-10 as described [15]. The purified preparation was free 
of cys. ai, crO and fi subunits, as judged by immuno-blots. 
Membranes from cyc- cells were obtained as in [16] and liver 
plasma membranes were prepared as in [17]. 
2.2. Adenylate cyclase assay 
Adenylate cyclase activity was determined [8] in a reaction 
mixture containing 50 mM TEA-HCl, pH 7.5, 1 mM IBMX, 1 
mM DTT, 0.1 mM or 1 mM EDTA, 2 mM purified creatine 
phosphate, creatine kinase (lOOrg/ml), myokinase (lOOgg/ml), 
adenosine deaminase (5 U/ml), 100 PM ATP (~Y-‘~P]ATP 
(3-25 x lo5 cpm), and the indicated concentrations of MgC12 
or MnClz in a volume of 100 pl. Prior to use myokinase and 
adenosine deaminase were centrifuged and the supernatant am- 
monium sulfate was removed. The pelleted enzymes were 
resuspended in water for use. After 15 min at 30°C reactions 
were stopped by the ZnCOs precipitation method [18] and the 
labelled CAMP was purified as in [19]. 
Results comparable to those shown were obtained in at least 
two separate experiments, each done in duplicate. I&O values 
were determined graphically and are averages + range from two 
experiments, each done in duplicate. 
2.3. Materials 
[(Y-~~P]ATP was purchased from ICN Pharmaceuticals. 
2’5’ddAdo was synthesized by Dr S.-M.H. Yeung in our 
laboratory. 7-0-Hemisuccinyl-7-deacetylforskolin was obtained 
from Calbiochem. Affigel-IO was from BioRad and wheat germ 
lectin Sepharose 6MB was from Pharmacia. Cyc- cells were 
kindly provided by Dr G. Schultz, Freie Universitat Berlin, Ger- 
many and antibodies to ays, ai, cr., and ,& subunits of the respec- 
tive C-proteins were gifts from Dr A. Spiegel, National In- 
stitutes of Health, Bethesda, MD. 
Other reagents were from commercial sources and were of the 
highest quality available. 
3. RESULTS 
3.1. P-site sensitivity of crude and purified 
adenylate cyclase 
In agreement with observations of others [7-l 11, 
we found that sensitivity of the particulate rat brain 
adenylate cyclase to inhibition by 2’5 ‘ddAdo was 
increased upon activation by metal ions and with 
prior activation by GTPyS or cholera toxin (table 
1). For example, in the presence of 2.1 mM Mg2+ 
the ICSO for 2’5’ddAdo was reduced from 
80 + 9 PM for the unstimulated enzyme to approx- 
imately 40 PM for GTP+- or cholera toxin- 
stimulated enzyme (table 1). Likewise, forskolin 
stimulated the brain enzyme, 6.0-fold with 2.1 mM 
Mg2+ and 5.3-fold with 10 mM Mg2+. However, 
these effects were actually accompanied by an in- 
crease in the IC~O for inhibition by 2 ‘5 ‘ddAdo 
(table 1). This is in contrast with observations on 
enzyme from pigeon breast muscle, rabbit liver, 
and wild type or cyc- S49 lymphoma cells [lo, 111, 
in which forskolin potentiated inhibition by 
2 ‘5 ‘ddAdo. 
The reduced sensitivity to P-site-mediated inhibi- 
tion of adenylate cyclase that was seen with for- 
skolin was neither species specific nor was it con- 
fined to crude particulate preparations of brain en- 
zyme. It was conceiveable, for example, that crude 
detergent extracts from brain tissue contained fac- 
tors that altered the effects of forskolin on 
adenylate cyclase or mediated its effect to reduce P- 
site sensitivity. Alternatively, since it is well known 
that a predominant form of adenylate cyclase in 
brain tissue is calmodulin sensitive, it may have 
been that the effect of forskolin was confined to 
this form of the enzyme. The effects of forskolin 
on 2’5 ‘ddAdo inhibition of crude and purified en- 
zyme from bovine brain are illustrated in fig.1. 
Forskolin caused a 2-fold increase in the ICSO for 
2’5 ‘ddAdo in the presence of 3 mM Mg2+ (from 
97 -t 3 to 200 PM) or 11 mM Mg2+ (from 32 + 4 to 
56 /IM) (fig.1, upper panel). With 3.5 mM Mn2+ 
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Table 1 
The effects of various stimuli on the relative sensitivity of particulate brain adenylate cyclase 
to inhibition by 2 ‘5 ‘-dideoxyadenosine 
ICse values for 2 ‘5 ‘dideoxyadenosine bM) 
Control Forskolin 
(100 rM) 
GTPyS 
(1OrM) 
CTx Mn2+ 
(1 mM) 
Forskolin + 
Mn2+ 
Mg2+ (mM) 
2.1 80 + 9 90+ 10 43 + 2 42 * 4 2.8 + 0.6 2.4 + 0.2 
10 19* 1 44+ 12 20 + 9 10 f 0 4.9 + 1.4 4.3 f 0.3 
Particulate adenylate cyclase from rat brain (8 to 14 ,ug protein/tube) was pretreated with 
GTPrS (10 PM; 15 min at 30°C) or cholera toxin (CTx 50 rg/ml + 500 FM GTP for 30 min 
at 20°C) and incubated as described in section 2.2 with a reaction mixture containing 100 PM 
GTP, 0.1 mM EDTA, 2.1 or 10 mM Mg’+, and varying concentrations of 2 ‘5 ‘ddAdo (0.1 to 
1000 pM). Initial activities in pmol cAMP/min per mg protein with 2.1 mM Mg2+ were: con- 
trol, 119; forskolin, 714 + 27; GTP$S, 284 f 17; CTx, 203 f 4; Mn’+, 869 f 5; forskolin + 
M&, 2916 + 39; and with 10 mM Mg2+ were: control, 231 + 23; forskolin, 1216 f 181; 
GTP+, 601 + 47; CTx, 317 f 34; Mn’+, 1245 f 48; forskolin + Mn’+, 4734 + 35. Values are 
expressed as averages + range from two separate xperiments, each done in duplicate 
3mM Mg2* 
IlmM Mg2+ 
3.5mM Mn2+ 
3mM Mg2’ 
1lmM Mg2+ 
3.5mM Mn2+ 
LO 80 120 160 200 uo 
Es0 for 2’5’ddAdo (yM) 
Fig. 1. Effects of forskolin and divalent cations to alter sensitivi- 
ty of crude and purified preparations of brain adenylate cyclase 
to inhibition by 2 ‘5 ‘ddAdo. Adenylate cyclase was assayed as in 
section 2.2 with a reaction mixture containing bovine serum 
albumin (1 mg/ml), 0.1% Lubrol PX, 1 mM EGTA, 100 pM 
ATP, and the indicated concentrations of metal ions, but with- 
out myokinase or adenosine deaminase. I&O values are averages 
f range from two experiments, each conducted in duplicate. 
Concentrations of 2 ‘5 ‘ddAdo were from 0.01 to 1000 PM. Solid 
bars: control; cross-hatched bars: 100 PM forskolin. Upper 
panel: detergent-dispersed a enylate cyclase from bovine brain 
(148 pg protein/ml) had the following initial activities, in pmol 
cAMP/min per mg protein, without forskolin: 3 mM Mg’+, 43; 
11 mM h;lg”, 56; 3.5 mM Mr?+, 1733; and with 1OOpM for- 
skolin: 3 mM Mg2+, 308; 11 mM Mg’+, 429; 3.5 mM Mn’+, 
6377. Lower panel: purified catalytic subunit from bovine brain 
was assayed without IBMX or ATP-regenerating system and 
had the following initial activities, in pmol cAMP/min per 10 yl 
enzyme, without forskolin: 3 mM Mg2+, 0.46; 11 mM Mg’+, 
0.67; 3.5 mM Mn’+, 1.73; and with 1OOpM forskolin: 3 mM 
forskolin increased the ICSO for 2’5 ‘ddAdo from 
1.4 f 0.1 to 4.3 + 0.3 PM. Although the purified 
enzyme from bovine brain exhibited a progressive 
loss in P-site sensitivity during its purification 
(fig. 1, compare upper and lower panels [cf. 4,6]), it 
retained sensitivity to stimulation by forskolin (cf. 
[ 141) and forskolin still caused a rightward shift in 
the concentration dependence for inhibition by 
2’5 ‘ddAdo (fig. 1). This was observed at all Mg2+ 
and Mn2+ concentrations tested (fig. 1, lower 
panel). These data imply that the effect of for- 
skolin to counter inhibition by P-site agonists is not 
caused by factors present in the crude detergent ex- 
tracts, but is a property of the catalytic subunit of 
the brain adenylate cyclase. 
The effect of forskolin to decrease P-site sen- 
sitivity was concentration dependent (fig.2), with 
effects being evident with as little as 1 PM for- 
skolin. The effect of forskolin on the I& for 
2’5’ddAdo appears to be saturable, suggesting that 
the opposing actions of forskolin and 2 ‘5 ‘ddAdo 
are not competitive. Indeed, analysis of the kinetics 
of these effects on adenylate cyclase showed that 
2’5 ‘ddAdo and forskolin acted in a nonlinear, 
noncompetitive manner with the purified enzyme 
(not shown). Similar results were obtained with the 
crude detergent-dispersed enzyme. These data 
would be consistent with there being distinct bind- 
ing domains on the catalytic subunit for forskolin 
and for P-site agonists. 
Mg’+, 1.72; 11 mM Mg2+, 2.26; 3.5 mM Mr?+, 10.73. Moreover, this effect of forskolin was not 
157 
Volume 248, number 1,2 FEBS LETTERS May 1989 
BOVINE BRAIN AOENVLATE CYCLASE 
1 
0 EXPT I 
0 EXPT II 
1 
I I 
0 10 20 30 LO 50 
Iforskolinl, pM 
Fig.2. Concentration dependence of the effect of forskolin on 
the I& for 2’S’ddAdo. Detergent-dispersed a enylate cyclase 
was incubated as in section 2.2, with 3.5 mM Mn*+. Concentra- 
tions of 2’5’ddAdo were from 0.01 to 1000 PM. IGO values are 
from two separate xperiments, each conducted in duplicate. 
restricted to inhibition by 2’5 ‘ddAdo, but was also 
seen with 2’d3 ‘AMP and adenosine (table 2). 
Thus, the forskolin-induced increase in the ICJO for 
2 ‘5 ‘ddAdo is a characteristic of the P-site and not 
of a particular agonist. The consistent 2- to 3-fold 
increase in the ICSO for the P-site agonists we 
observed with the brain enzyme, contrasts with the 
decreased ICSO expected from forskolin’s known 
effects on adenylate cyclase from other tissues (cf. 
[ 1 l] and below). 
A possible explanation for this distinct behavior 
Table 3 
Calmodulin-enhanced sensitivity to inhibition of purified 
adenylate cyclase by 2 ‘5 ‘-dideoxyadenosine 
Metal ICso values for 2 ‘5 ‘-dideoxyadenosine &M) 
Control Calmodulin 
(25 fig/ml) 
MgClz 
(10 mM) 31 *l 13 *3 
MnClz 
(2.5 mM) 5.5 + 2.0 1.8 + 0.5 
Purified adenylate cyclase from bovine brain cortex was in- 
cubated as described in section 2.2 with a reaction mixture con- 
taining bovine serum albumin (1 mg/ml), 3 mM dithiothreitol, 
0.1% Lubrol-PX, 108 PM ATP, and the indicated concentra- 
tions of metal. For reactions with calmodulin 50 pM Car& was 
added. Concentrations of 2’5’ddAdo were from 0.1 to 
1000 PM. Values averages + range from two experiments, each 
assayed in duplicate 
of the brain adenylate cyclase might be that this en- 
zyme had undergone proteolysis during its isola- 
tion. That this was not the case could be concluded 
from experiments with enzyme from bovine brain 
that was prepared in the presence or absence of an 
array of protease inhibitors (antipain, aprotinin, 
soybean trypsin inhibitor, leupeptin, chymostatin, 
pepstatin, phenylmethylsulfonyl f uoride, N-tosyl- 
L-phenylalanine chloromethyl ketone, No-p-tosyl- 
L-lysine chloromethyl ketone, benzamidine, and 
EGTA). Specific activities of both preparations 
were comparable. Moreover, the effects of for- 
Table 2 
Opposing actions of forskolin and different P-site analogs on detergent-dispersed a enylate cyclase from brain 
Control Forskolin (100 PM) 
Enzyme activity Inhibition Enzyme activity Inhibition 
(pmol/min per mg) (To) (pmol/min per mg) (70) 
No addition 1403 + 176 5081 + 237 
2’5’ddAdo ;lE$; 239+ 17 82.9 * 1.4 1938+ 91 61.8 + 2.7 
ss+ 3 93.7 t 0.7 668* 21 86.8 t 0.7 
2’d3’AMP (1OpM) 241f 11 82.6 + 1.5 1607 + 36 68.3 + 0.9 
(lOOrM) 97& 6 93.0 * 1.2 555 + 33 89.1 + 0.9 
Adenosine (ii $i 975 + 100 30.3 f 1.8 4138 + 189 18.4 + 5.9 
414+ 29 70.4 f 2.0 264Ozt 65 48.0 t 1.2 
Detergent-dispersed a enylate cyclase from bovine brain cortex (10 or 14.8 pg protein/tube) was incubated as 
described in section 2.2 with a reaction mixture containing bovine serum albumin (1 mg/ml), 0.1% Lubrol PX, 
1 mM EGTA, and 3.5 mM Mn 2+ but without myokinase or adenosine deaminase. Results are expressed as , 
means f SD from three separate xperiments, each done in duplicate 
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Fig.3. Forskolin-enhanced sensitivity of hepatic adenylate 
cyclase to inhibition by 2’5’ddAdo. Rat liver membranes 
(8.25 fig protein/tube) were incubated for 2 min at 37°C as 
described in section 2.2, in the presence of 3.5 mM Mn2+ and 
1 mM EGTA. Initial activities in pmol cAMP/min per mg pro- 
tein were: control, 13.6 (0); 100 PM forskolin, 223 (0). Values 
are averages of duplicate determinations in one of two similar 
experiments. See text for ICsc values. 
skolin to stimulate the enzyme and to diminish sen- 
sitivity to P-site inhibition were also unaffected by 
use of the protease inhibitors (not shown). 
3.2. Calmodulin-enhanced sensitivity to P-site 
inhibition 
Since brain adenylate cyclase is stimulated by 
Ca’+/calmodulin [4,14], the possible influence of 
calmodulin on the effects of forskolin and P-site 
sensitivity of the enzyme were examined. However, 
the results shown in fig.1 suggested that 
calmodulin did not alter the enzyme’s response to 
forskolin, since these experiments had been con- 
ducted in the presence of 1 mM EGTA. The 
presence of EGTA reduced activity of the crude en- 
zyme by 80% (not shown), due to the removal of 
calmodulin, but this did not alter the counteractive 
effects of forskolin and 2’5’ddAdo (fig.1, upper 
panel). Uncertain, though, was the effect of 
calmodulin on P-site sensitivity. When a saturating 
concentration of calmodulin (25 pg/ml) was added 
to the purified catalytic subunit, adenylate cyclase 
activity increased 3.2- and 2.1-fold with 10 mM 
Mg*+ and 2.5 mM Mn*+, respectively, in agree- 
ment with observations by Smigel [14]. This 
stimulation by calmodulin was accompanied by a 
2- to 3-fold increased sensitivity to inhibition by 
2 ‘5 ‘ddAdo (table 3), which contradicts the findings 
of Yeager et al. [4], also with adenylate cyclase 
from bovine brain. These workers reported no 
significant effect of calmodulin on the 1% (60 to 
80 /cM) for 3 ‘dAdo as P-site agonist. Although 
these workers reported increased sensitivity to P- 
site-mediated inhibition by preactivation with 
GPP(NH)P, the I& values for 2’5 ‘ddAdo 
(24 PM) and adenosine (260pM) [4] were 
significantly higher than we observed (cf. table 2), 
suggesting qualitative differences in the two en- 
zyme preparations. Our data suggest hat, as with 
Table 4 
Potentiative interaction of forskolin and 2’5 ‘-dideoxyadenosine in particulate 
adenylate cyclase from S49 cyc- cells 
Adenylate cyclase activity 
(pmol cAMP/min per mg protein) 
Control 2’5 ‘ddAdo 
(100 PM) 
Inhibition 
(%) 
Mn*+ (3.5 mM) 7.3 f 0.9 6.0 + 0.4 17 * 6 
Mn*+ (20 mM) 7.0 * 0.4 4.9 + 0.6 30 * 7 
Mn*+ (3.5 mM) + 
forskolin (1OOyM) 343 *71 65 * 7 81+2 
Mn*+ (20 mM) + 
forskolin (100 PM) 279 + 48 104 + 13 62 i 2 
Membranes (20 to 40 pg protein/tube) from cyc- variants of S49 lymphoma cells were 
incubated as described in section 2.2 with a reaction mixture containing 1 mM EDTA 
instead of 0.1 mM. Results are expressed as means + SD from three separate ex- 
periments, each done in duplicate 
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other activators of adenylate cyclase, calmodulin seem to be similar in brain and other tissues 
enhances sensitivity to P-site-mediated inhibition [11,16], it was surprising that the forskolin- 
and this is opposite to the effect of forskolin, al- stimulated form of the brain enzyme was actually 
though both effects are evidently on the catalytic less sensitive to P-site-mediated inhibition than was 
subunit of the brain enzyme. the unstimulated form. 
3.3. Forskolin-enhanced sensitivity to P-site 
inhibition in other tissues 
To rule out the possibility that the unique effect 
of forskolin on the brain enzyme might be due to 
an artifact introduced in our laboratory, we tested 
the effects of forskolin on P-site sensitivity in rat 
liver membranes and S49 cyc- membranes (cf. 
[ 111). With the adenylate cyclase of rat liver mem- 
branes (fig.3), forskolin induced a pronounced 
leftward shift in the inhibition curve for 
2’5 ‘ddAdo (1C50 1 .O + 0.1 ,uM) relative to the con- 
trol (1C50 19 + 6 PM). With S49 cyc- membranes 
(table 4), forskolin also potentiated inhibition of 
adenylate cyclase by 2 ‘5 ‘ddAdo, consistent with 
observations by Florio and Ross [l 11. The data in- 
dicate that adenylate cyclases from these tissues 
and from brain differ significantly in the character 
of the effects that forskolin induces in the enzyme’s 
catalytic subunits. 
4. DISCUSSION 
From available evidence the loci for inhibition of 
adenylate cyclase by P-site agonists and activation 
of the enzyme by forskolin or calmodulin are on 
the enzyme’s catalytic subunit itself [3-6,8,11,14]. 
It is thus likely that for the adenylate cyclases of 
liver or S49 cyc- cells, for example, one conse- 
quence of activation of the enzyme by forskolin is 
a conformational change in the catalytic unit that 
specifically affects the P-site domain, resulting in 
increased affinity for the P-site specific ligands. 
Data reported here would suggest further that an 
analogous conformational change in the catalytic 
subunit of the brain enzyme may be induced by 
Cazf/calmodulin (table 3). However, it is this 
structural change affecting the P-site domain that 
apparently does not occur when the brain 
adenylate cyclase is stimulated by forskolin. These 
observations lend further support to the idea that 
the calmodulin-sensitive form of brain adenylate 
cyclase is structurally different from hormone- 
sensitive forms of the enzyme in this and other 
tissues. 
Adenylate cyclase from brain exhibits the typical 
metal-dependent, non-competitive inhibition by P- 
site specific agents, as well as enhancement of sen- 
sitivity to inhibition by 2’5 ‘ddApo upon activation 
via the stimulatory G, protein by cholera toxin and 
upon proteolytic activation with the sperm pro- 
tease ninhibin in the presence of GTPyS [6]. 
However, the effect of forskolin to potentiate P- 
site-mediated inhibition that is typical of adenylate 
cyclase preparations from a variety of tissues 
[lO,l l] was absent in the brain enzyme. This un- 
usual behavior of the brain enzyme was not due to 
an obvious artifact in the assay procedure, nor was 
it likely a consequence of proteolysis of the brain 
enzyme. The effect of forskolin to diminish the in- 
hibitory potency of 2 ‘5 ‘ddAdo was seen with both 
crude and purified preparations of the brain 
adenylate cyclase and in the presence or absence of 
calmodulin and/or functionally active G-proteins. 
Since other effects of forskolin on adenylate 
cyclase, such as enzyme activation or protection 
against inactivation by heat or N-ethylmaleimide, 
Other exceptions exist to the general rule that 
stimulated forms of adenylate cyclase are more 
sensitive to inhibition by P-site agonists than are 
unstimulated forms. We have observed with 
adenylate cyclase from rat brain, for example, that 
NH4+ ions increased activity but decreased its sen- 
sitivity to P-site-mediated inhibition [20]. This ef- 
fect, while not directly on the catalytic unit is likely 
due to altered interactions of the catalytic unit and 
Gs~, thereby affecting the conformation of the 
catalytic unit and consequently the sensitivity to in- 
hibition by P-site agonists. In other studies, al- 
though millimolar Ca2+ inhibits adenylate cyclases, 
Ca2+ was reported to enhance sensitivity of the en- 
zyme from guinea pig lung to inhibition by P-site 
agonists [21]. This may be due to calcium’s 
mimicking or substituting for Mn2+ or Mg2+ at the 
metal-binding domain of the catalytic unit and in- 
ducing sufficient conformational changes in the 
catalytic unit for the enzyme to exhibit P-site sen- 
sitivity. Divalent cation, though, may not induce 
these changes in the catalytic units of all adenylate 
cyclases. The enzyme from ram [5] or bovine [6,12] 
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sperm, for example, exhibits poor P-site sensitivity 
(I& values of 0.5 to 1 mM for adenosine), even in 
the presence of optimally stimulatory concentra- 
tions of Mn*+. The sperm enzyme, though, does 
not exhibit the same structure-activity relationship 
for inhibitory agonists as does the enzyme from 
somatic cells, in that adenosine was typically more 
potent than 2’dAdo or 2’5’ddAdo [5,6,12]. Thus, 
while virtually all mammalian adenylate cyclases 
exhibit a P-site, the enzymes may be distinguished 
by the structures and characteristics of these in- 
hibitory binding domains. 
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